Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITAL: Lapatinib combinations in HER2+ metastatic breast cancer
NCT01013740Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of lapatinib in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Progression Free Survival at 27 weeks. Started Nov 2009; status: completed.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01013740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01013740.